Jan Davisson

612 total citations
8 papers, 451 citations indexed

About

Jan Davisson is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Jan Davisson has authored 8 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 4 papers in Public Health, Environmental and Occupational Health and 3 papers in Molecular Biology. Recurrent topics in Jan Davisson's work include Acute Myeloid Leukemia Research (7 papers), Acute Lymphoblastic Leukemia research (4 papers) and Pneumocystis jirovecii pneumonia detection and treatment (2 papers). Jan Davisson is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Acute Lymphoblastic Leukemia research (4 papers) and Pneumocystis jirovecii pneumonia detection and treatment (2 papers). Jan Davisson collaborates with scholars based in United States. Jan Davisson's co-authors include Farhad Ravandi, Hagop M. Kantarjian, Jianqin Shan, Jörge E. Cortes, Guillermo Garcia‐Manero, Jean‐Pierre J. Issa, Susan O’Brien, Ahmed Aribi, Xuelin Huang and Carlos E. Bueso‐Ramos and has published in prestigious journals such as Blood, Cancer and Bone Marrow Transplantation.

In The Last Decade

Jan Davisson

8 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Davisson United States 6 333 228 120 93 52 8 451
James M. Rossetti United States 10 256 0.8× 195 0.9× 137 1.1× 34 0.4× 42 0.8× 37 384
Francesca Buchi Italy 10 263 0.8× 210 0.9× 97 0.8× 23 0.2× 28 0.5× 12 345
R. M. Stone United States 9 189 0.6× 129 0.6× 60 0.5× 45 0.5× 44 0.8× 13 304
Ansu Abu Alex India 9 202 0.6× 150 0.7× 32 0.3× 94 1.0× 68 1.3× 22 334
RR Ellison United States 5 246 0.7× 164 0.7× 66 0.6× 140 1.5× 52 1.0× 6 339
Rebeca Rodríguez‐Veiga Spain 10 171 0.5× 147 0.6× 49 0.4× 45 0.5× 117 2.3× 39 326
BL Powell United States 6 211 0.6× 148 0.6× 68 0.6× 77 0.8× 42 0.8× 7 310
Federica Cattina Italy 9 187 0.6× 136 0.6× 80 0.7× 51 0.5× 41 0.8× 35 282
Curtis A. Lachowiez United States 10 267 0.8× 168 0.7× 88 0.7× 53 0.6× 48 0.9× 35 319
Catharina Müller‐Thomas Germany 8 218 0.7× 145 0.6× 82 0.7× 35 0.4× 34 0.7× 19 299

Countries citing papers authored by Jan Davisson

Since Specialization
Citations

This map shows the geographic impact of Jan Davisson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Davisson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Davisson more than expected).

Fields of papers citing papers by Jan Davisson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Davisson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Davisson. The network helps show where Jan Davisson may publish in the future.

Co-authorship network of co-authors of Jan Davisson

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Davisson. A scholar is included among the top collaborators of Jan Davisson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Davisson. Jan Davisson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Lima, Marcos de, Hagop M. Kantarjian, S. Faderl, et al.. (2009). Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplantation. 43(11). 839–843. 64 indexed citations
2.
Kantarjian, Hagop M., Susan O’Brien, Xuelin Huang, et al.. (2007). Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Cancer. 109(6). 1133–1137. 132 indexed citations
3.
Aribi, Ahmed, Gautam Borthakur, Farhad Ravandi, et al.. (2007). Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 109(4). 713–717. 86 indexed citations
4.
Silva, Leandro de Pádua, Marcos de Lima, Hagop M. Kantarjian, et al.. (2007). Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.. Blood. 110(11). 1468–1468. 5 indexed citations
5.
Kantarjian, Hagop M., Guillermo Garcia‐Manero, Susan O’Brien, et al.. (2007). Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.. Blood. 110(11). 115–115. 5 indexed citations
6.
Kantarjian, Hagop M., Susan O’Brien, Jianqin Shan, et al.. (2006). Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 109(2). 265–273. 79 indexed citations
7.
Jabbour, Elias, Susan O’Brien, Farhad Ravandi‐Kashani, et al.. (2006). Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).. Blood. 108(11). 2655–2655. 1 indexed citations
8.
Gandhi, Varsha, John Michael Kilpatrick, William Plunkett, et al.. (2005). A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 106(13). 4253–4260. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James M. Rossetti Breakdown of academic impact, for papers by Francesca Buchi Breakdown of academic impact, for papers by R. M. Stone Breakdown of academic impact, for papers by Ansu Abu Alex Breakdown of academic impact, for papers by RR Ellison Breakdown of academic impact, for papers by Rebeca Rodríguez‐Veiga Breakdown of academic impact, for papers by BL Powell Breakdown of academic impact, for papers by Federica Cattina Breakdown of academic impact, for papers by Curtis A. Lachowiez Breakdown of academic impact, for papers by Catharina Müller‐Thomas
Rankless by CCL
2026